Yahoo
NYSE - Nasdaq Real Time Price USD

Kenvue Inc. (KVUE)

19.31 -0.12 (-0.62%)
As of 3:58:43 PM EDT. Market Open.
Trade Kenvue on Coinbase
Chart Range Bar
Loading chart for KVUE

What's happening with KVUE?

12m ago
Powered by Yahoo Scout

Kenvue’s central development remains Kimberly-Clark’s pending acquisition, with the related note-exchange process extended to November 2, 2026. Tender participation was already high across Kenvue’s seven debt series, while valuation commentary remains divided between cash-flow upside and execution risks. The latest available market data shows KVUE down 0.57% in the current regular session.

Powered by Yahoo Scout
  • Previous Close 19.43
  • Open 19.31
  • Bid 19.30 x 1990000
  • Ask 19.30 x 2810000
  • Day's Range 19.25 - 19.48
  • 52 Week Range 14.02 - 20.13
  • Volume 6,689,590
  • Avg. Volume 22,341,340
  • Market Cap (intraday) 37.09B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 22.45
  • EPS (TTM) 0.86
  • Earnings Date Oct 30, 2026
  • Forward Dividend & Yield 0.84 (4.31%)
  • 1y Target Est 19.50
  • Morningstar Rating Rating available with Stock Picks access

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

www.kenvue.com

21,780

Full Time Employees

December 28

Fiscal Year Ends

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KVUE
17.25%
S&P 500 (^GSPC)
13.08%

1-Year Return

KVUE
41.15%
S&P 500 (^GSPC)
12.34%

3-Year Return

KVUE
21.55%
S&P 500 (^GSPC)
88.01%

5-Year Return

KVUE
24.36%
S&P 500 (^GSPC)
68.42%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3.96B
Earnings 456M
Profit Margin 11.53%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
1B
2B
3B
9.0%
10.0%
11.0%
12.0%

Analyst Insights

View More

Analyst Price Targets

18.00 Low
19.50 Average
19.31 Current
23.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/11/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 20 -> 19

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.76%

  • Return on Assets (ttm)

    6.99%

  • Return on Equity (ttm)

    15.58%

  • Revenue (ttm)

    15.41B

  • Net Income Avi to Common (ttm)

    1.66B

  • Diluted EPS (ttm)

    0.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.11B

  • Total Debt/Equity (mrq)

    81.62%

  • Levered Free Cash Flow (ttm)

    1.91B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: